Skip to main content
NewslettersWatchlist

Theratechnologies(TH-T)
TSX

Today's Change
Real-Time Last Update
Day Low1.80
Day High1.92
Open:1.89
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Automated Summaries - The Globe and Mail
Closing Bell: Theratechnologies down on Monday (TH)
GlobeNewswire
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
AI-generated - The Globe and Mail
Theratechnologies: Top 10 Undervalued Biotechnology Industry Stocks (TH)
GlobeNewswire
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
GlobeNewswire
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
GlobeNewswire
Theratechnologies Appoints Elina Tea to its Board of Directors
GlobeNewswire
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
Baystreet
Stocks in play: Theratechnologies Inc.
GlobeNewswire
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
GlobeNewswire
Theratechnologies Announces Update on its Preclinical Oncology Research Program
GlobeNewswire
Theratechnologies Appoints Jordan Zwick to its Board of Directors
GlobeNewswire
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
GlobeNewswire
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
GlobeNewswire
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
GlobeNewswire
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
Baystreet
Stocks in play: Theratechnologies Inc.
GlobeNewswire
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
GlobeNewswire
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
GlobeNewswire
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
The Globe and Mail
Market movers: Stocks that saw action on Wednesday - and why
GlobeNewswire
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
GlobeNewswire
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application
AllPennyStocks.com
Will This Dual-Listed Bio-Pharma Catch New Year Action?
Newswire.ca
Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement
GlobeNewswire
Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose
AI-generated - The Globe and Mail
Theratechnologies: Top 10 Undervalued Biotechnology Industry Stocks (TH)
Baystreet
Stocks in play: Theratechnologies Inc.
GlobeNewswire
Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award
AI-generated - The Globe and Mail
Theratechnologies: Top 10 Undervalued Healthcare Sector Stocks on TSX (TH)
AI-generated - The Globe and Mail
Theratechnologies: Top 25 Undervalued Toronto Stock Exchange Stocks (TH)

Profile

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.